Accès gratuit
Med Sci (Paris)
Volume 26, Numéro 3, Mars 2010
Page(s) 291 - 296
Section M/S revues
Publié en ligne 15 mars 2010
  1. Williams SA, Greene WC. Regulation of HIV-1 latency by T-cell activation. Cytokine 2007; 39 : 63–74.
  2. Narlikar GJ, Fan HY, Kingston RE. Cooperation between complexes that regulate chromatin structure and transcription. Cell 2002; 108 : 475–87.
  3. Treand C, Du Chêne I, Bres V, et al. Requirement for SWI/SNF chromatin-remodeling complex in Tatmediated activation of the HIV-1 promoter. EMBO J 2006; 25 : 1690–9.
  4. Ganesh L, Burstein E, Guha-Niyogi A, et al. The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes. Nature 2003; 426 : 853–7.
  5. Yeung ML, Benkirane M, Jeang KT. Small non-coding RNAs, mammalian cells, and viruses: regulatory interactions ? Retrovirology 2007; 4 : 74.
  6. Triboulet R, Benkirane M. Implication de la voie des microARN dans la réplication du VIH. Med Sci (Paris) 2007; 23 : 590–2.
  7. Triboulet R, Mari B, Lin YL, et al. Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science 2007; 315 : 1579–82.
  8. Chun TW, Justement JS, Lempicki RA, et al. Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci USA 2003; 100 : 1908–13.
  9. Corbeau P. Interfering RNA and HIV: reciprocal interferences. PLoS Pathog 2008; 4 : e1000162.
  10. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387 : 188–91.
  11. Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. Jama 1999; 282 : 1627–32.
  12. Maldarelli F, Palmer S, King MS, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007; 3 : e46.
  13. Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41 : 4531–6.
  14. Shen L, Siliciano RF. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol 2008; 122 : 22–8.
  15. Bailey JR, Sedaghat AR, Kieffer T, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 2006; 80 : 6441–57.
  16. Llewellyn N, Zioni R, Zhu H, et al. Continued evolution of HIV-1 circulating in blood monocytes with antiretroviral therapy: genetic analysis of HIV-1 in monocytes and CD4+ T cells of patients with discontinued therapy. J Leukoc Biol 2006; 80 : 1118–26.
  17. Cumont MC, Monceaux V, Viollet L, et al. TGF-beta in intestinal lymphoid organs contributes to the death of armed effector CD8 T cells and is associated with the absence of virus containment in rhesus macaques infected with the simian immunodeficiency virus. Cell Death Differ 2007; 14 : 1747–58.
  18. Aquaro S, Calio R, Balzarini J, et al. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res 2002; 55 : 209–25.
  19. Stevens M, De Clercq E, Balzarini J. The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention. Med Res Rev 2006; 26 : 595–625.
  20. Rohr O, Marban C, Aunis D, Schaeffer E. Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells. J Leukoc Biol 2003; 74 : 736–49.
  21. Darbinian-Sarkissian N, Darbinyan A, Otte J, et al. p27(SJ), a novel protein in St John’s Wort, that suppresses expression of HIV-1 genome. Gene Ther 2006; 13 : 288–95.
  22. Berna A, Bernier F, Chabriere E, Perera T, Scott K. DING proteins; novel members of a prokaryotic phosphate-binding protein superfamily which extends into the eukaryotic kingdom. Int J Biochem Cell Biol 2008; 40 : 170–5.
  23. Mok HP, Lever A. Waking Up the Sleepers: HIV Latency and Reactivation. J Formos Med Assoc 2008; 107 : 909–14.
  24. Geeraert L, Kraus G, Pomerantz RJ. Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu Rev Med 2008; 59 : 487–501.
  25. Wang FX, Xu Y, Sullivan J, et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005; 115 : 128–37.
  26. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 1998; 188 : 83–91.
  27. Mai A. The therapeutic uses of chromatin-modifying agents. Expert Opin Ther Targets 2007; 11 : 835–51.
  28. Siliciano JD, Lai J, Callender M, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007; 195 : 833–6.
  29. Contreras X, Barboric M, Lenasi T, Peterlin BM. HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog 2007; 3 : 1459–69.
  30. Martinez V, Autran B. Les HIV controllers : une nouvelle entité évolutive de l’infection par le VIH ? Med Sci (Paris) 2008; 24 : 7–9.
  31. Schwartz C, Le Douce V, Cherrier T, et al. Un virus tapi dans l’ombre : les bases moléculaires de la latence du VIH-1. Partie I : la physiologie de la latence du VIH-1. Med Sci (Paris) 2010; 26 : 159–63.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.